Madrigal Pharmaceuticals, Inc.
MDGL
Rangering i aksjer
#2018
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Aksjekurs
$447.16
Markedsverdi
$10.33B
Endring (1 dag)
-0.57%
Endring (1 år)
1.88%
Land
US
Handel Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
EPS for Madrigal Pharmaceuticals, Inc. (MDGL)
EPS per June 2026 TTM: $-12.89
Ifølge de siste økonomiske rapportene og aksjekursen til Madrigal Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) $-12.89. Ved slutten av 2023 hadde selskapet en EPS på $-19.99, en økning sammenlignet med EPS-en i 2022 som var $-17.23.
EPS-historikk for Madrigal Pharmaceuticals, Inc. fra 2001 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-12.89 | -41.14% |
| 2024 | $-21.90 | 9.55% |
| 2023 | $-19.99 | 16.02% |
| 2022 | $-17.23 | 17.77% |
| 2021 | $-14.63 | 11.76% |
| 2020 | $-13.09 | 176.74% |
| 2019 | $-4.73 | 113.06% |
| 2018 | $-2.22 | -12.60% |
| 2017 | $-2.54 | -49.90% |
| 2016 | $-5.07 | -98.74% |
| 2015 | $-401.56 | 1,211.43% |
| 2014 | $-30.62 | -31.16% |
| 2013 | $-44.48 | 20.25% |
| 2012 | $-36.99 | 5.26% |
| 2011 | $-35.14 | 8.16% |
| 2010 | $-32.49 | -139.84% |
| 2009 | $81.55 | -184.87% |
| 2008 | $-96.09 | 40.38% |
| 2007 | $-68.45 | -23.97% |
| 2006 | $-90.03 | -16.88% |
| 2005 | $-108.31 | 26.00% |
| 2004 | $-85.96 | 92.52% |
| 2003 | $-44.65 | -57.51% |
| 2002 | $-105.09 | 2,209.67% |
| 2001 | $-4.55 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -234.37% |
US
|
|
| $-7.98 | -38.09% |
US
|
|
| $-5.29 | -58.96% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -315.21% |
NL
|
